RHOA mutation in cancer cells activated the phosphoinositide-3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) signaling pathway and reduced the C–X–C motif chemokine ligand (CXCL)10/CXCL11, recruiting effectors of CD8 + T lymphocytes. Here, MTOR is linked to cancer.